novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

As grandes limitações dos Antivitamínicos K (Varfarina, Acenocumarol)

15 Setembro 2014

Pedro Marques da Silva
Internista
Hospital de Sta. Marta,
CHLC, Lisboa

NOACs o que são

15 Setembro 2014
0

NOACs o benefício adicional da toma única diária

15 Setembro 2014
0

-->